1 / 29

Statistical considerations

Statistical considerations. Drs. Jan Welink. Training workshop: Assessment of Interchangeable Multisource Medicines, Kenya, August 2009. Statistical considerations. Bioequivalence. The primary concern in bioequivalence assessment is to limit the risk of a false declaration of equivalence.

Samuel
Download Presentation

Statistical considerations

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Statistical considerations Drs. Jan Welink Training workshop: Assessment of Interchangeable Multisource Medicines, Kenya, August 2009

  2. Statistical considerations

  3. Bioequivalence The primary concern in bioequivalence assessment is to limit the risk of a false declaration of equivalence. Statistical analysis of the bioequivalence trial should demonstrate that the clinically significant difference in bioavailability is unlikely….. [WHO working document multisource (generic) pharmaceutical products: Guidelines on registration requirements to establish interchangeability, Nov. 2005]

  4. Bioequivalence 2 pharmaceutical products Test Reference Bioequivalent??

  5. Bioequivalence Cmax AUC Tmax Important PK parameters Cmax: the observed maximum concentration of a drug  measure of the rate of absorption AUC: area underthe concentration-time curve  measure of the extent of absorption tmax: time at which Cmax is observed  measure of the rate of absorption

  6. Statistical considerations How similar is similar?

  7. Statistical considerations

  8. Statistical considerations Statistical test should take into account… • The consumer (patient) risk of erroneously accepting bioequivalence (primary concern health authorities) • Minimize the producer (pharmaceutical company) risk of erroneously rejecting bioequivalence • Choice: • two one-side test procedure • confidence interval ratio T/R 100 (1-2) •  set at 5% (90% CI)

  9. Statistical considerations

  10. Statistical considerations Consumer Risk • The risk of declaring two product BE when they’re not is called the ‘consumer risk’ • In statistical terms, this is a Type I error • The risk of rejecting the null hypothesis when it’s true • The consumer risk is set at 5%

  11. Statistical considerations Producer Risk • The risk of declaring two products NOT BE when they truly are BE is called the ‘producer risk’ • In statistical terms, this is a Type II error • The risk of accepting the null hypothesis when it’s false

  12. Statistical considerations The risks are related • If the consumer risk is reduced, the producer risk increases • In statistical terms, if you lower the acceptable risk of making a Type I error, the risk of making a Type II error increases

  13. Statistical considerations Average Bioequivalence: two drug products are bioequivalent ‘on the average’ when the (1-2α) confidence interval around the Geometric Mean Ratio falls entirely within 80-125% (regulatory control of specified limit)

  14. Statistical considerations Some International Criteria

  15. Statistical considerations

  16. Statistical considerations Least Square Means from ANOVA t-statistic with 0.05 in one tail Standard Error

  17. Statistical considerations BE Limits • The concept of the 20% difference is the basis of BE limits (goal posts) • If the concentration dependent data were linear, the BE limits would be 80-120% • On the log scale, the BE limits are 80-125% • The 90%CI must fit entirely within specified BE limits e.g. 80-125%

  18. Statistical considerations Variables..: • Log transformation: • For all concentration dependent pharmacokinetic variables (AUC and Cmax) • Analysis of log-transformed data by means of ANOVA (analysis of variance) • includes usually formulation, period, sequence or carry-over, and subject factors • parametric test (normal theory)

  19. Statistical considerations • The sources of variance in the model are • Product • Period • Sequence • Subject (Sequence) • Residual variance These account for all the inter-subject variability This estimates Intra-subject variability

  20. Statistical considerations • The width of the 90%CI depends on • The magnitude of the WSV (ANOVA-CV (residual variance)) • The number of subjects in the BE study • The bigger the WSV (within- or intra-subject variability), the wider the CI • If the WSV is high, more subjects are needed to give statistical power compared with when the WSV is low

  21. Statistical considerations intra-subject variability analytical variability unexplained random variability subject by formulation interaction ANOVA CV

  22. Statistical considerations 125 100 80

  23. Statistical considerations why log-transformation:

  24. Statistical considerations Why parametric testing and not non-parametric: applicant: after log transformation not normal distributed! • based upon test for normality, however these are insensitive and it concerns a small study • normally after log transformation AUC and Cmax are normal distributed • reason for non-normality should be explained

  25. Outliers • ‘Outliers’ • Definition: • aberant/irregular values (e.g. no plasma concentration, ‘late’ high concentrations….)

  26. Outliers • ‘Outliers’ • Explanation: • vomiting? • non-compliant volunteers? • bioanalytical failure? • individual pharmacokinetics? • protocol violations? • ……

  27. Outliers • ‘Outliers’ • Handling: • “…pharmacokinetic data can only be excluded based on non-statistical reasons that have been defined previously in the protocol. • Exclusion of data can never be accepted on the basis of statistical analysis or for pharmacokinetic reasons alone, because it is impossible to distinguish between formulation effects and pharmacokinetic effects. • Results of statistical analyses with and without the excluded subjects should be provided.” (excerpt from Q&A Doc Ref: EMEA/CHMP/EWP/40326/2006)

  28. Power calculation

  29. End

More Related